Elevation Oncology (ELEV) to Release Earnings on Thursday

Elevation Oncology (NASDAQ:ELEV) is expected to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect Elevation Oncology to post earnings of ($0.20) per share for the quarter.

Elevation Oncology (NASDAQ:ELEV) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. On average, analysts expect Elevation Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Elevation Oncology Stock Performance

Shares of ELEV stock opened at $0.35 on Wednesday. The company’s fifty day moving average price is $0.38 and its 200-day moving average price is $0.54. The stock has a market cap of $20.52 million, a PE ratio of -0.42 and a beta of 1.65. The company has a current ratio of 17.77, a quick ratio of 17.77 and a debt-to-equity ratio of 0.45. Elevation Oncology has a 12 month low of $0.22 and a 12 month high of $4.48.

Institutional Investors Weigh In On Elevation Oncology

A hedge fund recently raised its stake in Elevation Oncology stock. Bank of America Corp DE raised its holdings in Elevation Oncology, Inc. (NASDAQ:ELEV) by 42.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 56,839 shares of the company’s stock after acquiring an additional 16,962 shares during the quarter. Bank of America Corp DE owned approximately 0.10% of Elevation Oncology worth $32,000 as of its most recent filing with the Securities & Exchange Commission. 83.70% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research analysts have issued reports on ELEV shares. HC Wainwright lowered their price objective on Elevation Oncology from $6.00 to $1.00 and set a “buy” rating for the company in a research note on Friday, March 21st. Stephens restated an “equal weight” rating and issued a $1.00 price objective (down from $5.00) on shares of Elevation Oncology in a report on Monday, March 24th. Citigroup lowered Elevation Oncology to a “market perform” rating in a report on Friday, March 21st. Piper Sandler cut Elevation Oncology from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $10.00 to $0.70 in a research report on Friday, March 21st. Finally, Leerink Partnrs downgraded shares of Elevation Oncology from a “strong-buy” rating to a “hold” rating in a report on Thursday, March 20th. Seven equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $3.39.

Elevation Oncology Company Profile

Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.